Biocardia reports fourth quarter and full year 2023 business highlights and financial results

Sunnyvale, calif., march 27, 2024 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended december 31, 2023 and filed its annual report on form 10-k with the securities and exchange commission.
BCDA Ratings Summary
BCDA Quant Ranking